Glasgow has approximately 20,000 citizens living with cancer; when including families and carers this increases to 70,000. ICJ was developed as research advised of the growing need and complexity of issues faced by people affected by cancer (PABC).
The aims of ICJ within the 5 years of the programme are to:
- Invite all with a new cancer diagnosis in Glasgow to have an HNA and individual care plan developed.
- Provide the support of a dedicated named Link Officer to everyone with a cancer diagnosis.
- Facilitate the delivery of effective Health and Social care support solutions, based on HNA outcomes.
- Identify ways to improve service delivery for PABC
Baseline research was carried out by the NHS Health Improvement team; patients, carers and medical staff provided 100% support for the proposed development of ICJ and the link worker model being delivered uniquely within a social care setting.
A steering group with representatives from all partners informed the development of ICJ. In addition, we have established a service users advisory group where patients, their families and carers are actively involved in informing and shaping solutions
The ICJ programme is fully funded by Macmillan Cancer Support for 5 years and a robust business plan was developed to support this funding bid.
ICJ has a number of structures supporting the development, including:
- A governance board chaired by the Executive Director of Financial Services and including Directors from all partners who form the decision making body
- Steering group with representation from all partners who shape and inform the development and delivery
- Staff have been at the forefront of the development of ICJ since the programme began and through action learning sets and reviewing case studies inform ICJ developments
- Patient reference group who provide an expert voice on what needs to change to improve the cancer journey
One of the main barriers to accessing ICJ was data sharing between NHSGG&C and GCC. To overcome this, ICJ established a data sharing protocol between the NHS and GCC. This inventive approach allows the NHS to share information on all new cancer diagnosis within Glasgow with the ICJ service. This provides access to ICJ for all PABC at diagnosis.
A robust business plan was developed to secure the £3.2 million funding for the 5 year programme. In addition, Prostate Cancer UK has provided additional funding to enable us to develop the service even further.
ICJ was initially a pilot covering 5 cancers, independent evaluation was carried out by St Andrews University. The results from this informed a board decision to extend to all cancers in October 2014.